Key result
Pregabalin treatment for 4 weeks improved heart rate variability, reducing the low frequency-high frequency ratio compared to placebo.
Why the study?
Does pregabalin improve heart rate variability in patients with diabetes and painful peripheral neuropathy?
RCT (n=40)
Does pregabalin improve heart rate variability in patients with diabetes and painful peripheral neuropathy?
A 4-week treatment with pregabalin significantly improved heart rate variability, pain, anxiety, and quality of life in patients with painful diabetic peripheral neuropathy.
Answers are grounded in this paper and cite their sources.
Pregabalin may enhance autonomic markers in diabetic neuropathy; leaves open whether this improves outcomes or warrants routine use.
Many studies have demonstrated that low heart rate variability (HRV) is a risk for high mortality and morbidity in patients with cardiovascular diseases. The primary purpose of the study was to evaluate whether pregabalin improves HRV in patients with diabetes and painful peripheral neuropathy. Resting heart rates were collected by using the LifeShirt System, developed by VivoMetrics (Ventura, Calif), at baseline and at the end of a 4-week intervention of pregabalin or placebo in patients with painful diabetic peripheral neuropathy. Heart rate variability analysis was performed on the collected R-R intervals using the Vivo- VMLA-036-00 3 Logic of the LifeShirt system. Of the 40 patients enrolled in the study, 70% completed the end of 4-week assessments (n = 15 in pregabalin and n = 14 in placebo). Compared with placebo, pregabalin treatment resulted in significant improvement in HRV measured by frequency domain analysis, that is, a reduction in low frequency-high frequency ratio (−1.30 ± 2.89 vs 0.37 ± 0.33, P = 0.03) and power of normalized low frequency (−0.049 ± 0.092 vs 0.0066 ± 0.023, P = 0.02), as well as an increase in power of normalized high frequency (0.039 ± 0.094 vs −0.038 ± 0.066, P = 0.02). Furthermore, pregabalin resulted in greater reduction of pain and symptoms of anxiety and greater improvement of quality of life. The improvement of HRV measures were not correlated with change of those measures. In conclusion, 4-week pregabalin treatment improved HRV in patients with painful diabetic peripheral neuropathy. Trial Registration: NCT00573261 (clinicaltrials.gov) Abbreviations: HRV - heart rate variability, VAS - visual analog scale, BID - twice daily, RSA - respiratory sinus arrhythmia, VLF - very low frequency, LF - low frequency, HF - high frequency, ANN - mean of all R-R intervals, SDNN - standard deviation of R-R intervals, RMSSD - root mean square of successive differences, SDANN - standard deviation of the averages of R-R intervals for all 5-minute segments within the block, PNN50 - number of N-N intervals that differed by more than 50 milliseconds from adjacent intervals divided by the total number of all N-N intervals, NPS - Neuropathic Pain Scale, BPI - Modified Brief Pain Inventory-Short Form, STAI - State-Trait Anxiety Inventory Scale, BDI - Beck Depression Inventory
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2011) conducted an RCT in Painful diabetic peripheral neuropathy (n=40). Pregabalin vs. Placebo was evaluated on Low frequency-high frequency ratio (p=0.03). Pregabalin treatment for 4 weeks improved heart rate variability, reducing the low frequency-high frequency ratio compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: